PD-L1 is a biomarker of real-world clinical outcomes for anti-CTLA-4 plus anti-PD-1 or anti-PD-1 monotherapy in metastatic melanoma

Eva Ellebaek, Shawez Khan, Lars Bastholt, Henrik Schmidt, Charlotte Aaquist Haslund, Marco Donia, Inge Marie Svane

9 Citationer (Scopus)

Fingeraftryk

Dyk ned i forskningsemnerne om 'PD-L1 is a biomarker of real-world clinical outcomes for anti-CTLA-4 plus anti-PD-1 or anti-PD-1 monotherapy in metastatic melanoma'. Sammen danner de et unikt fingeraftryk.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science

Medicine and Dentistry

Neuroscience